Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC1318 Cdki Hydrochloride
Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4
More description
DCC1317 Cdk9-in-37
Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)
More description
DCC1316 Cdk9/cyct1-in-93
Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity
More description
DCC1315 Cdk9/bet-in-40
Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel
More description
DCC1314 Cdk9 Degrader 45
Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer
More description
DCC1313 Cdk8-in-iv
Novel CDK8 inhibitor
More description
DCC1312 Cdk8-in-iii
Novel CDK8 inhibitor
More description
DCC1311 Cdk8-in-ii
Novel CDK8 inhibitor
More description
DCC1310 Cdk8-in-i
Novel potent CDK8 inhibitor
More description
DCC1309 Cdk8-in-4k
Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition
More description
DCC1308 Cdk8-in-32
Novel highly potent, selective, permeable CDK8 inhibitor
More description
DCC1307 Cdk8-in-3
Novel inhibitor of CDK8
More description
DCC1306 Cdk8-in-18
Novel potent and selective inhibitor of CDK8, also modulating CDK19
More description
DCC1305 Cdk8/19-in-52h
Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells
More description
DCC1304 Cdk8/19-in-51
Novel potent and selective dual inhibitor of CDK8 and CDK19
More description
DCC1303 Cdk8 Inhibitor W-34
Novel potent CDK8 inhibitor
More description
DCC1302 Cdk6/pim1 Inhibitor 51
Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo
More description
DCC1301 Cdk6 Degrader Cp-10
Novel potent CDK6 degrader
More description
DCC1300 Cdk4 Inhibitor V
Potent, ATP-binding site-targeting Cdk4/D1 inhibitor
More description
DCC1299 Cdk12-in-7
Novel potent and selective CDK12 inhibitor
More description
DCC1298 Cddhqd-in-1
Novel selective cdDHQD inhibitor
More description
DCC1297 cd4528
Novel agonist for the vitamin D receptor (VDR)
More description
DCC1296 cd4420
Novel agonist for the vitamin D receptor (VDR)
More description
DCC1295 cd4409
Novel agonist for the vitamin D receptor (VDR)
More description
DCC1294 Cd33 Pre-mrna Splicing Modulator 1
Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools
More description
DCC1293 Cd22 Glycan Ligand
Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA
More description
DCC1292 Cd2019
Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.
More description
DCC1291 cd11359
Novel telomerase inhibitor
More description
DCC1290 Cd10847
Novel Caspase-1 inhibitor
More description
DCC1289 Cd08108
Novel MC1R agonist
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X